We work side by side with our partners to enable greater access to life improving pharmaceuticals
PharmaJet’s Needle-free Systems provide increased vaccine effectiveness, a preferred patient and caregiver experience, and a proven path to commercialization. They are also safe, fast, and easy-to-use.
The PharmaJet Tropis® device for intradermal injections received authorization to apply the CE Mark in May 2016. An FDA Master File was established in August of 2017 as a precursor to 510(k) and Tropis received WHO Pre-Qualification (PQS) in June of 2018.
The innovative PharmaJet Stratis® Needle-Free Injector has U.S. FDA 510(k) marketing clearance, CE Mark and WHO PQS certification to deliver medications and vaccines intramuscularly or subcutaneously. In August 2014, the PharmaJet Stratis Needle-free Injector was approved for delivery of an influenza vaccine to deliver needle-free flu shots.
The PharmaJet Team
Chris Cappello
President and Chief Executive Officer
Mr. Cappello was appointed Chief Operating Officer in 2018, and President and Chief Executive Officer in 2020. In this position, he is responsible for running all facets of the business. Chris has over 15 years of direct management experience in medical device development and sales, and has spent his career managing the successful design, development, clearance and launch of both reusable and high volume disposable medical devices. Prior to joining PharmaJet, he drove the development of disruptive medical device technologies at companies such as AlloSource and Applied Medical. Chris has a Bachelor of Science degree in Mechanical Engineering from Colorado State University and his Project Management Professional certification.
Jeffrey A. Jordan
Chief Financial Officer
Mr. Jordan has more than 25 years of experience in corporate finance. In his previous role, he directed the global finance functions for the Laboratory Products Group of Thermo Fisher Scientific, supporting $1.9B in annual revenue and 10,000 employees. Jeff has worked in several industries including life science tools, telecommunications and industrial chemicals. He has extensive experience in strategic planning, forecasting, significant capital investments, acquisitions and integration activities. Jeff has a Bachelor of Science degree in Mechanical Engineering from the United States Military Academy at West Point and an MBA from the University of Maryland.
Paul LaBarre
Vice President, Global Business Development
Mr. LaBarre has 25 years of Medical Technology experience across the innovation value chain including regulatory, strategy, research, product development, and market analysis. He has held key business development roles at prominent healthcare organizations including UNICEF and PATH, as well as other health innovation organizations. Most recently he was Senior Vice President, Access and Innovation for SightLife, the world’s leading eye bank. Paul holds a Bachelor of Science degree in Mechanical Engineering from Northwestern University, a Master of Medical Engineering from the University of Washington, and an MBA from Mount Vernon Nazarene University.
Nathalie Landry
Chief Scientific Officer
Ms. Landry has over 30 years of experience in the successful development of a new technology platform as well as innovative vaccines and pharmaceuticals from proof-of-concept to late-stage clinical trials and regulatory approval. Prior to joining PharmaJet, she was Executive Vice President, Scientific and Medical Affairs at Medicago, an international leader in plant-based technology producing vaccines and therapeutics, where she led all R&D activities, analytical and process development, preclinical and clinical development, medical affairs, and pharmacovigilance activities. She has published over 25 articles in major international scientific journals, two book chapters and is co-inventor on 8 patent families. Nathalie holds a Master of Microbiology-Immunology and an MBA from the Université Laval.
Erin K. Spiegel, Ph.D.
Vice President, Clinical and Regulatory Affairs
As a molecular geneticist with over 20 years of experience, Dr. Spiegel’s research, publications, and patents span gene mapping, molecular mechanisms of disease, and delivery mechanisms of DNA and adenovirus-based vaccines. She has established Quality Systems and GMP production for design and manufacturing of vaccines and devices and provided Regulatory and Clinical strategic planning for various drugs, biologics and medical devices. As Vice President, Clinical and Regulatory Affairs at PharmaJet, she combines her scientific knowledge with her regulatory and clinical experience to advance needle-free injection technology and its promise for widespread vaccinations. She has served on multiple IACUC and IRB committees. Erin received her Bachelor of Science degree from the University of Nebraska and her PhD in Biophysics and Genetics from the University of Colorado.
Troy Chapman
Vice President, Operations
Mr. Chapman has more than 30 years of experience in the medical device industry across the fields of electrophysiology, electrosurgery, embolic coils and radioactive pharmaceuticals. Prior to joining PharmaJet he held engineering and leadership positions at Cardinal Health, ConMed and Covidien where he was responsible for research, development, and manufacturing. Troy has a Bachelor of Science degree in Mechanical Engineering from Purdue University.
Laurence J. Marton, M.D.
Dr. Marton serves as a consultant to industry and to nonprofit, government, and academic institutions. In the nonprofit sector, Dr. Marton is an Emeritus Member of the Board of Trustees of the American Association for Cancer Research Foundation and is on the Board of Directors of Cancer Commons. In the for-profit sector, he serves on the Boards of Directors of Cellsonics, Matternet, Microsonic Systems, Nanotics, Omniox (also serving as Executive Chair), RenovoRx, and xCures and is an advisor to Assurance Health Data, PharmaJet, and the Precision Medicine World Conference.
Previously, Dr. Marton was Dean of the University of Wisconsin Medical School and Chaired the Department of Laboratory Medicine at UCSF, where he was a Professor in the Departments of Laboratory Medicine and Neurological Surgery. Dr. Marton received his MD from the Albert Einstein College of Medicine.
Cornelia L. Dekker, M.D.
Medical Director, Stanford-LPCH Vaccine Program and Professor of Pediatrics (Infections Diseases), Stanford University School of Medicine. Vaccine development, clinical research and vaccine safety are core elements of Corry’s 32-year career. The first two decades were spent with Wellcome Research Labs, Lederle Biologicals and finally a nine-year term with Chiron Corporation, where she served as Medical Director, then VP, Clinical Research and Medical Affairs for the Vaccine Division. Corry then blended her vaccine experience with an academic position at Stanford University School of Medicine in 1999 where she does applied research in vaccines through NIH-sponsored vaccine clinical trials and conducted vaccine safety research funded by CDC. Dr. Dekker received her BS and MD from Michigan State University College of Human Medicine and residency and specialization in Pediatric Infectious Disease at Duke University Medical Center.
Paul Mendelman, M.D.
As a physician/scientist Paul has researched and published extensively on the role antibiotic resistance mechanisms play in infectious disease, particularly with Haemophilus influenza. As a pediatrician, his contributions include vaccine safety, efficacy, effectiveness and immunogenicity studies in influenza, hepatitis B, Haemophilus type B, pneumococcal conjugate and other vaccines. While serving as VP Clinical Research at Aviron, then VP and Group Leader, Clinical Development at MedImmune, Paul was integral to the clinical and commercial development of the intranasal influenza vaccine FluMist. He currently serves as Chief Medical Officer and Executive VP of LigoCyte Pharmaceuticals, a clinical-stage biologic drug development company focused on respiratory and gastrointestinal indications utilizing a proprietary virus-like particle (VLP) technology. Dr. Mendelman received his BS and MD from The Ohio State University, and is board certified in Pediatrics and Pediatric Infectious Diseases.
Melissa Malhame
Ms. Malhame has over 25 years of experience in business development, strategic sales, and marketing for major global vaccine providers such as Gavi, The Vaccine Alliance, Dynavax and Merck. She has supported global health investments in new vaccine candidates and expanded access to existing vaccines, working with the WHO, UNICEF and The Bill and Melinda Gates Foundation. Previously she was head of Market Shaping at Gavi, where she managed $1 billion of annual vaccine funding, and was accountable for ensuring the supply of vaccines at affordable prices, setting long-term access strategies, and leading Alliance relationships with the vaccine industry. Melissa has a Bachelor of Arts degree in Economics & International Affairs from Lafayette College, and an MBA from Cornell University.
Marie Mazur, PharmD
Ms. Mazur has served on the Board of Directors since 2020 and was appointed Chairman in 2023. She is a global business executive with 30+ years of pharmaceutical and vaccine industry experience including Sanofi, 3M, GSK and CSL Seqirus. She also serves on the Strategic Advisory Group of the Partnership for Influenza Vaccine Introduction (PIVI), a program from the Task Force for Global Health in partnership with the US Centers for Disease Control and Prevention. Marie holds a doctorate in Pharmacy and master’s degree in Regulatory Affairs from Paris (France) University, and an International Executive Degree in Business Administration (IEP) from INSEAD Business School.
Chris Cappello
Mr. Cappello was appointed Chief Operating Officer of PharmaJet in 2018, and President and Chief Executive Officer in 2020. In this position, he is responsible for running all facets of the business. Mr. Cappello has over 15 years of direct management experience in medical device development and sales, and has spent his career managing the successful design, development, clearance and launch of both reusable and high volume disposable medical devices. Previously Chris drove the development of disruptive medical device technologies at companies such as AlloSource and Applied Medical. He has a Bachelor of Science degree in Mechanical Engineering from Colorado State University and his Project Management Professional certification.
Nathalie Landry
Ms. Landry has over 30 years of experience in the successful development of a new technology platform as well as innovative vaccines and pharmaceuticals from proof-of-concept to late-stage clinical trials and regulatory approval. Prior to joining PharmaJet, she was Executive Vice President, Scientific and Medical Affairs at Medicago, an international leader in plant-based technology producing vaccines and therapeutics, where she led all R&D activities, analytical and process development, preclinical and clinical development, medical affairs, and pharmacovigilance activities. She has published over 25 articles in major international scientific journals, two book chapters and is co-inventor on 8 patent families. Nathalie holds a Master of Microbiology-Immunology and an MBA from the Université Laval
Erin K. Spiegel, Ph.D.
As a molecular geneticist with over 20 years of experience, Dr. Spiegel’s research, publications, and patents span gene mapping, molecular mechanisms of disease, and delivery mechanisms of DNA and adenovirus-based vaccines. She has established Quality Systems and GMP production for design and manufacturing of vaccines and devices and provided Regulatory and Clinical strategic planning for various drugs, biologics and medical devices. As Vice President, Clinical & Regulatory Affairs at PharmaJet, she combines her scientific knowledge with her regulatory and clinical experience to advance needle-free injection technology and its promise for widespread vaccinations. She has served on multiple IACUC and IRB committees. Erin received her Bachelor of Science degree from the University of Nebraska and her PhD in Biophysics and Genetics from the University of Colorado.
Marie Mazur, PharmD
Chairman
Ms. Mazur has served on the Board of Directors since 2020 and was appointed Chairman in 2023. She is a global business executive with 30+ years of pharmaceutical and vaccine industry experience including Sanofi, 3M, GSK and CSL Seqirus. She also serves on the Strategic Advisory Group of the Partnership for Influenza Vaccine Introduction (PIVI), a program from the Task Force for Global Health in partnership with the US Centers for Disease Control and Prevention. Marie holds a doctorate in Pharmacy and master’s degree in Regulatory Affairs from Paris (France) University, and an International Executive Degree in Business Administration (IEP) from INSEAD Business School.
Chris Cappello
President and Chief Executive Officer
Mr. Cappello was appointed Chief Operating Officer in 2018, and President and Chief Executive Officer in 2020. In this position, he is responsible for running all facets of the business. Mr. Cappello has over 15 years of direct management experience in medical device development and sales, and has spent his career managing the successful design, development, clearance and launch of both reusable and high volume disposable medical devices. Previously Chris drove the development of disruptive medical device technologies at companies such as AlloSource and Applied Medical. He has a Bachelor of Science degree in Mechanical Engineering from Colorado State University and his Project Management Professional certification.
Heather Callender-Potters
Chief Advocate & Shareholder Relations Officer
One of the co-founders and active in the management of PharmaJet, Heather has 23 years of private equity fund management and international investment experience across multiple jurisdictions, managing individual investments and financial investment consortiums. She has a BA in International Management from Claremont McKenna College and an MBA from Wharton, the University of Pennsylvania.
Tony Allard
Mr. Allard is President of Hearthstone Investments. He holds a BA and LLB from the University of Alberta.
Spike Buckley
Mr. Buckley has a background as a commercial real estate developer, with investments spanning the US and Canada. He is an active angel investor in high- tech and bio-tech companies, which includes medical devices and tools that aid in drug delivery and diagnostic activities. Spike is an active board participant in the Colorado Veterinary Medical Foundation, Alameda Corridor Business Improvement District and CryptoMill Technologies. He holds a BA in Economics from the University of Colorado.
Gordon Clancy
Mr. Clancy is a private investor, and a former Managing Partner of Citigroup Venture Capital International, a global private equity fund that invested primarily in emerging markets in a wide variety of industries including pharmaceuticals and medical equipment. Prior to his involvement in private equity, he worked in various roles in the Citigroup capital markets and trading businesses. He holds a Bachelor of Arts degree in Commerce and Economics from University of Toronto and an MBA from the Rotman School of Management, University of Toronto.
Nanette Cocero, Ph.D.
Dr. Cocero is a recognized leader in the global pharmaceutical industry with 25+ years of experience most recently as the Global President of Pfizer Vaccines. In this role, she led a diverse, >$30B portfolio and drove the development, marketing and delivery of innovative vaccines including the Pfizer-BioNTech COVID-19 vaccine. She holds a Bachelor of Science degree in Chemistry from Cornell University, an MBA from The Wharton Business School and a doctorate in Pharmacology from the University of Pennsylvania.
Kim Duncan
Mr. Duncan is currently the CEO of ConserV Bioscience, a UK-based late-stage vaccine development company. He began his career at Goldman Sachs in 1987 and went on to have a 20-year career in the investment business where he led teams taking principal risk. He has been an active angel investor since 2006, focusing on equity investments in promising, early-stage biotechnology companies and currently serves on the boards of six companies. He earned a Bachelor of Science degree in Electrical Engineering from Yale University, an MS in Biotechnology and an MS in Physiology and Pharmacology both from Georgetown University.
John Hynes
Mr. Hynes is the Chief Financial Officer and a Board member for QC Ware Corp, a software company focused on high-powered algorithms for drug discovery and finance. Previously, he spent 30 years as a professional investor with Fidelity Investments, Emso Asset Management and Watermark Management. He has extensive experience with health care, biotech, and technology companies, both public and private. He has a BA in Economics from Dartmouth College and an MBA from The Wharton School at the University of Pennsylvania.
Markus Pedriks
Mr. Pedriks is an investor, as well as a professional private equity fund manager. He is skilled in operational leadership and entrepreneurial activities, in Europe and North America, in health, media, telecommunications, entertainment and real estate. He holds a BA in Economics from McGill University and an MBA from IMD, Lausanne.
Marian Wentworth
Ms. Wentworth, a seasoned global health executive, is President and CEO of Management Sciences for Health, a nonprofit organization that works with low- and middle-income markets across 30 countries to strengthen their health systems. Previously she held executive roles at Merck & Co., most recently as Vice President, Global Vaccines Strategy and Innovation, where she was responsible for strategy for the $6 billion global vaccines business. She is also Chair of the Board of Medsource, a privately held group purchasing organization in Kenya. Marian holds a Bachelor of Arts degree in Mathematics from Harvard University.